(ACIU) AC Immune - Ratings and Ratios
Crenezumab, Semorinemab, ACI-24.060, PI-2620, ACI-35.030
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 71.3% |
| Value at Risk 5%th | 103% |
| Relative Tail Risk | -11.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.67 |
| Alpha | 14.67 |
| CAGR/Max DD | 0.17 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.356 |
| Beta | 0.879 |
| Beta Downside | 1.037 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.40% |
| Mean DD | 32.23% |
| Median DD | 32.40% |
Description: ACIU AC Immune January 01, 2026
AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharma focused on neurodegenerative diseases caused by protein misfolding. Its proprietary SupraAntigen and Morphomer platforms generate biologics and small-molecule candidates that selectively bind misfolded proteins such as amyloid-β, Tau, α-synuclein and TDP-43.
The lead therapeutic assets include Crenezumab (a conformation-specific anti-amyloid-β antibody) and Semorinemab (an anti-Tau monoclonal antibody designed to block inter-neuronal Tau spread). Additional pipeline programs target Down-syndrome-related Alzheimer’s (ACI-24.060), Parkinson’s disease (ACI-7104.056), and an active-immunization approach (ACI-35.030) that elicits endogenous antibodies against phosphorylated Tau. Diagnostic efforts feature PI-2620 (a Tau PET tracer for AD and non-AD tauopathies) and ACI-12589 (an α-syn PET tracer for differential diagnosis of multiple system atrophy).
AC Immune maintains strategic collaborations with major pharma players-Genentech, Janssen, Eli Lilly and Life Molecular Imaging-providing both milestone payments and co-development expertise. As of the latest 10-Q, the company held roughly $120 million in cash and equivalents, giving it an estimated 18-month runway at current burn rates, while R&D expense has risen ~35 % year-over-year, reflecting accelerated Phase II/III activity.
From a market perspective, the global neurodegenerative-disease therapeutics market is projected to exceed $150 billion by 2030, driven by an aging population and unmet clinical need; AC Immune’s focus on protein-misfolding mechanisms aligns with the sector’s shift toward disease-modifying therapies, which command higher valuation multiples than symptomatic treatments.
For a deeper quantitative view, consider reviewing ValueRay’s analyst dashboard for ACIU.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -71.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA -45.43 > 1.0 |
| NWC/Revenue: 353.6% < 20% (prev 207.9%; Δ 145.7% < -1%) |
| CFO/TA -0.27 > 3% & CFO -46.8m > Net Income -71.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (99.1m) vs 12m ago -1.73% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 2.10% > 50% (prev 17.06%; Δ -14.95% > 0%) |
| Interest Coverage Ratio: -398.5 > 6 (EBITDA TTM -69.6m / Interest Expense TTM 180.0k) |
Altman Z'' -13.72
| A: 0.09 (Total Current Assets 113.7m - Total Current Liabilities 98.3m) / Total Assets 171.6m |
| B: -2.45 (Retained Earnings -419.8m / Total Assets 171.6m) |
| C: -0.35 (EBIT TTM -71.7m / Avg Total Assets 207.9m) |
| D: -3.82 (Book Value of Equity -417.5m / Total Liabilities 109.2m) |
| Altman-Z'' Score: -13.72 = D |
Beneish M -4.00
| DSRI: 0.15 (Receivables 402.0k/25.4m, Revenue 4.37m/41.7m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.43 (AQ_t 0.30 / AQ_t-1 0.21) |
| SGI: 0.10 (Revenue 4.37m / 41.7m) |
| TATA: -0.15 (NI -71.9m - CFO -46.8m) / TA 171.6m) |
| Beneish M-Score: -4.26 (Cap -4..+1) = AAA |
What is the price of ACIU shares?
Over the past week, the price has changed by +2.06%, over one month by +6.77%, over three months by -1.42% and over the past year by +31.44%.
Is ACIU a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACIU price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.2 | 165.4% |
| Analysts Target Price | 9.2 | 165.4% |
| ValueRay Target Price | 3.4 | -1.4% |
ACIU Fundamental Data Overview January 26, 2026
P/E Forward = 11.236
P/S = 85.1372
P/B = 4.704
Revenue TTM = 4.37m CHF
EBIT TTM = -71.7m CHF
EBITDA TTM = -69.6m CHF
Long Term Debt = 4.66m CHF (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.04m CHF (from shortTermDebt, last quarter)
Debt = 4.66m CHF (from shortLongTermDebtTotal, last quarter)
Net Debt = -23.1m CHF (from netDebt column, last quarter)
Enterprise Value = 181.4m CHF (285.2m + Debt 4.66m - CCE 108.5m)
Interest Coverage Ratio = -398.5 (Ebit TTM -71.7m / Interest Expense TTM 180.0k)
EV/FCF = -3.80x (Enterprise Value 181.4m / FCF TTM -47.7m)
FCF Yield = -26.30% (FCF TTM -47.7m / Enterprise Value 181.4m)
FCF Margin = -1091 % (FCF TTM -47.7m / Revenue TTM 4.37m)
Net Margin = -1644 % (Net Income TTM -71.9m / Revenue TTM 4.37m)
Gross Margin = -1331 % ((Revenue TTM 4.37m - Cost of Revenue TTM 62.6m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = 1.06 (Enterprise Value 181.4m / Total Assets 171.6m)
Interest Expense / Debt = 0.99% (Interest Expense 46.0k / Debt 4.66m)
Taxrate = 21.0% (US default 21%)
NOPAT = -56.7m (EBIT -71.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.16 (Total Current Assets 113.7m / Total Current Liabilities 98.3m)
Debt / Equity = 0.07 (Debt 4.66m / totalStockholderEquity, last quarter 62.4m)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -23.1m / EBITDA -69.6m)
Debt / FCF = 0.48 (negative FCF - burning cash) (Net Debt -23.1m / FCF TTM -47.7m)
Total Stockholder Equity = 86.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.57% (Net Income -71.9m / Total Assets 171.6m)
RoE = -83.51% (Net Income TTM -71.9m / Total Stockholder Equity 86.1m)
RoCE = -79.07% (EBIT -71.7m / Capital Employed (Equity 86.1m + L.T.Debt 4.66m))
RoIC = -65.85% (negative operating profit) (NOPAT -56.7m / Invested Capital 86.1m)
WACC = 9.02% (E(285.2m)/V(289.8m) * Re(9.15%) + D(4.66m)/V(289.8m) * Rd(0.99%) * (1-Tc(0.21)))
Discount Rate = 9.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 8.53%
Fair Price DCF = unknown (Cash Flow -47.7m)
EPS Correlation: 44.39 | EPS CAGR: 99.91% | SUE: 0.71 | # QB: 0
Revenue Correlation: 35.55 | Revenue CAGR: 104.7% | SUE: 0.01 | # QB: 0
EPS next Year (2026-12-31): EPS=-0.61 | Chg30d=-0.009 | Revisions Net=+1 | Growth EPS=+11.7% | Growth Revenue=+643.9%